Morningstar
•
Oct 30, 2026
Incyte Corporation: Incyte Earnings: Opzelura Settlement and Latarcibart Improve Outlook Ahead of Jakafi Patent Loss
Summary
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Illumina, Inc.
Oct 30, 2026
•
ILMN
Analyst Report: Alnylam Pharmaceuticals, Inc.
Oct 30, 2026
•
ALNY
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Gilead Sciences, Inc.
Oct 30, 2026
•
GILD
Analyst Report: Alnylam Pharmaceuticals, Inc.
Oct 30, 2026
•
ALNY
